14 citations
,
July 2021 in “Bioscience Reports” Activating Tgr5 may help treat hair loss and bone loss.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Vitamin D3 is a safe and effective alternative to steroids for treating alopecia areata, with fewer side effects.
December 2014 in “Turk Dermatoloji Dergisi” Topical Saw Palmetto and Trichogen Veg Complex increased hair count by 11.9% and improved hair growth in 48% of men with hair loss.
December 2008 in “Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ” Antioxidants improved hair growth in alopecia areata patients regardless of disease duration.
January 2019 in “Journal of clinical and cosmetic dermatology” Combining laser light therapy and growth factor treatment improves hair growth in people with hair loss.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
June 2026 in “Journal of Cosmetic Dermatology” Combination drug therapy improves hair growth and patient care for androgenetic alopecia.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
Baricitinib works better than methotrexate for severe alopecia areata.
3 citations
,
May 2018 in “Journal of the Egyptian Womenʼs Dermatologic Society” Platelet-Rich Plasma treatment helps hair regrowth in people with mild Alopecia Areata, improving their quality of life with minimal side effects.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
July 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” AA-PRP injections significantly promote hair growth but need better study design for clear efficacy.
3 citations
,
June 2020 in “Journal of Dermatological Treatment” Triamcinolone acetonide is slightly more effective than betamethasone for hair regrowth in localized alopecia areata.
July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
8 citations
,
January 2020 in “Indian Dermatology Online Journal” PRP works faster and is a safe alternative to steroids for treating alopecia areata.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
2 citations
,
September 2025 in “Journal of Dermatological Treatment” Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
January 2026 in “Journal of Community Medicine and Health Solutions” PP405 shows promise as a new, effective treatment for hair loss with minimal side effects.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
January 2023 in “Annals of Dermatology” Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.
September 2022 in “Indian Journal of Dermatology, Venereology and Leprology”
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.